Pritumumab-based ADC

About Nascent Biotech

Nascent Biotech is a public, clinical-stage biotechnology company focused on developing human antibody and cytokine-based therapies for cancer. Its core strategy is to mimic the body's natural, multi-targeted immune response by combining selected biomolecules into therapeutic 'cocktails,' a departure from standard single-agent monoclonal antibody approaches. The company's lead candidate, Pritumumab, has completed Phase I safety studies and is preparing for pivotal Phase II trials in orphan-designated cancers, representing a critical inflection point. However, the company faces significant financial and operational challenges, including a delisting from the OTCBB as it seeks capital to fund its next development phase.

Therapeutic Areas

Other Undisclosed Cancers Drugs